← Back to Search

Chemotherapy

Stereotactic body radiotherapy (SBRT) for Pancreatic Cancer

Phase 2
Waitlist Available
Led By Kimberly Johung, MD, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing if adding a new targeted therapy drug to the standard of care chemotherapy regimen before surgery will improve outcomes in patients with borderline resectable pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With and Without R0 Resection
Secondary outcome measures
Acute Coryza
Neoadjuvant Therapy
Neoadjuvant Therapy
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: patients with borderline resectable pancreatic adenocarcinomaExperimental Treatment2 Interventions
Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic body radiotherapy (SBRT)
2015
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,846 Previous Clinical Trials
2,736,470 Total Patients Enrolled
Kimberly Johung, MD, PhDPrincipal InvestigatorYale University
1 Previous Clinical Trials
28 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
2017. "Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03099265.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top